LOXL2 and breast carcinoma: Immunohistochemistry (IHC) depicted elevated levels of LOXL2 in fulvestrant‐resistant breast cancer organoids compared to fulvestrant‐sensitive organoids, with no significant variance in LOX expression (Figure 5H).